BusinessNanoString Technologies Highlights Presentation of Multiple Prosigna/PAM50 and Immuno-Oncology Studies at the 39th Annual CTRC-AACR San Antonio Breast Cancer SymposiumBy Nasdaq OMXDec 5, 2016, 10:23 PM UTC
BusinessCascadian Therapeutics Announces Presentation of Tucatinib in Combination Therapy in Patients with Cutaneous HER2+ Metastatic Breast CancerBy Nasdaq OMXOct 10, 2016, 11:10 AM UTC
BusinessCompanion Diagnostics Market worth 5.58 Billion USD by 2019; Transparency Market ResearchBy Nasdaq OMXSep 27, 2016, 12:04 PM UTC
BusinessCascadian Therapeutics Announces Approval of Nonproprietary Name “tucatinib” for Lead Product Candidate ONT-380By Nasdaq OMXAug 31, 2016, 8:02 PM UTC
BusinessPreclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXApr 20, 2016, 12:05 PM UTC
BusinessProvista Diagnostics Announces New Chief Financial Officer and Expands Commercial Team ExpertiseBy Nasdaq OMXApr 6, 2016, 1:00 PM UTC
BusinessOncothyreon Announces First Patient Dosed in Randomized Phase 2 ONT-380 Combination Trial in Patients with HER2-Positive Breast CancerBy Nasdaq OMXFeb 29, 2016, 1:00 PM UTC
BusinessPeregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy ConferencesBy Nasdaq OMXJan 20, 2016, 1:05 PM UTC
